The Development of meso -Methyl-BODIPY Conjugates with Boc- seco -CBI and Cabozantinib: The Practical Challenges of Red-Light-Activated Prodrugs for Anticancer PDT
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Natalia S Kuzmina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lobachevsky State University of Nizhny Novgorod, Gagarina av. 23, Nizhny Novgorod 603950, Russian Federation. Hauptthemen laut MEDLINE: Boron Compounds, Photochemotherapy, Pyridines, Light. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Latest studies highlight boron-dipyrromethene (BODIPY) with a meso-methyl moiety as a promising photoremovable protecting group due to its activation within the phototherapeutic window. While BODIPYs inherently generate ROS and act as photosensitizers, few studies have explored combining their photouncaging capability with photodynamic therapy (PDT). Herein, we developed novel meso-methyl-BODIPY conjugates of the DNA alkylator Boc-seco-CBI and the multikinase inhibitor cabozantinib derivative activated by green or red light. To enhance the photodecaging efficiency of the conjugates, heavy atoms (Br, I) were introduced, and the boron atom was alkylated. The synthesized compounds were characterized for key photophysical and photochemical properties, including quantum yields of singlet oxygen generation, fluorescence, photolysis, and cytostatic release. It was shown that green-light irradiation of halogenated Boc-seco-CBI conjugates enabled rapid cytostatic release (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lobachevsky State University of Nizhny Novgorod, Gagarina av. 23, Nizhny Novgorod 603950, Russian Federation.
ORCID-Profile: Galina P Gribova, Irina V Balalaeva, Alexey Yu Fedorov, Vasilii F Otvagin
Förderung
- Russian Science Foundation
Zitieren
APA
Kuzmina, N. S., Gribova, G. P., Pnachina, E. M., Krylova, L. V., Fedotova, E. A., Balalaeva, I. V., Fedorov, A. Y., & Otvagin, V. F. (2025). The Development of meso -Methyl-BODIPY Conjugates with Boc- seco -CBI and Cabozantinib: The Practical Challenges of Red-Light-Activated Prodrugs for Anticancer PDT. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00343
Vancouver
Kuzmina NS, Gribova GP, Pnachina EM, Krylova LV, Fedotova EA, Balalaeva IV, et al. The Development of meso -Methyl-BODIPY Conjugates with Boc- seco -CBI and Cabozantinib: The Practical Challenges of Red-Light-Activated Prodrugs for Anticancer PDT. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00343
BibTeX
@article{Kuzmina2025,
author = {Kuzmina, Natalia S and Gribova, Galina P and Pnachina, Elizaveta M and Krylova, Lubov V and Fedotova, Ekaterina A and Balalaeva, Irina V and Fedorov, Alexey Yu and Otvagin, Vasilii F},
title = {The Development of meso -Methyl-BODIPY Conjugates with Boc- seco -CBI and Cabozantinib: The Practical Challenges of Red-Light-Activated Prodrugs for Anticancer PDT},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00343}
}
EUVIMED